ZIMLAB137.20

Zim Laboratories Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersANUHPHRVALIANTLABAHCLALBERTDAVDWANBURYHALEOSLABSBAJAJHCARETHEMISMEDMcap ₹734 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations367.4379.0374.4396.8
Other Income5.25.811.410.9
Total Income372.6384.8385.8407.7
Expenses
+ Cost of Materials Consumed177.7155.0164.0180.2
+ Purchases of Stock-in-Trade7.811.67.56.4
+ Changes in Inventories-14.11.3-6.1-11.8
+ Employee Benefit Expense53.360.863.968.5
+ Finance Costs6.911.413.213.5
+ Depreciation & Amortisation16.020.120.020.5
+ Other Expenses101.3106.7115.1125.3
Total Expenses349.0366.8377.6402.6
EBITDA41.343.730.028.2
EBIT25.423.610.07.7
Profit
PBT before Exceptional Items23.618.08.25.1
Pretax Income23.618.08.25.1
+ Current Tax0.94.73.43.3
+ Deferred Tax5.51.2-1.0-2.0
Tax Expense6.45.82.41.4
Net Income17.212.25.83.7
+ Net Income — Continuing Ops17.212.25.83.7
+ Other Comprehensive Income-0.2-0.02.12.1
Total Comprehensive Income17.012.17.95.8
Net Income to Common17.212.25.83.7
Minority Interest-0.0-0.00.0-0.0
Per Share
Basic EPS3.542.501.190.82
Diluted EPS3.542.501.190.82
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.02.12.1
+ Items NOT to be Reclassified to P&L-0.5-0.8-0.10.0
+ Tax on Items NOT to be Reclassified-0.2-0.00.0
+ Tax on Items NOT to be Reclassified — alt tag-0.2
+ Items to be Reclassified to P&L0.10.52.22.0
Comprehensive Income — Owners of Parent17.012.17.96.2
Comprehensive Income — Non-controlling Interests-0.0-0.00.0-0.1
Per Share — as-filed variants
Basic EPS — Continuing Operations3.542.501.190.82
Diluted EPS — Continuing Operations3.542.501.190.82
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit196.0211.2209.0222.0
Gross Margin %53.3455.7255.8355.94
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)23.618.08.25.1
Net Income Adj (tax-effected)17.212.25.83.7
EPS Adj3.542.501.190.82
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.00
Filed Debt Equity0.000.000.000.01
Filed Dscr0.020.020.010.01
Filed Iscr0.040.030.02-0.01
Paid Up Equity Capital48.748.753.553.5
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.